MARKET

NVS

NVS

Novartis
NYSE
97.54
+0.26
+0.27%
Opening 11:05 04/24 EDT
OPEN
98.55
PREV CLOSE
97.28
HIGH
98.55
LOW
97.44
VOLUME
803.77K
TURNOVER
0
52 WEEK HIGH
108.78
52 WEEK LOW
88.83
MARKET CAP
199.38B
P/E (TTM)
13.74
1D
5D
1M
3M
1Y
5Y
BMO Capital Maintains Market Perform on Novartis, Raises Price Target to $116
Benzinga · 6h ago
Company News for Apr 24, 2024
NASDAQ · 7h ago
UPDATE 1-Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump. The company's shares up 4% before the bell. Biogen has cut jobs and abandoned controversial drug Aduhelm to boost growth. Company says its new drug Leqembi recorded global sales of about $19 million.
Reuters · 9h ago
Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety
Benzinga · 11h ago
EUROPE RESEARCH ROUNDUP-Akzo Nobel, Galp, Randstad
Analysts revise their ratings and price targets on several European companies. Akzo Nobel, Galp and Randstad among those revised. Adidas, AB Foods and AB Foods raise their targets for the day. Randstad and RBC raise to outperform from sector perform in their reports.
Reuters · 13h ago
FDA Approves Novartis' Lutathera For Pediatric Gastroenteropancreatic Neuroendocrine Tumors
NASDAQ · 18h ago
Why Novartis Stock Topped the Market on Tuesday
Novartis beat analyst estimates for its first quarter and raised guidance for 2024. The pharmaceutical company's stock price rose 2.27% on Tuesday. The shares did better than the S&P 500 index. The company boosted net sales by 11% year over year to $11.8 billion.
The Motley Fool · 22h ago
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Novartis receives FDA approval for its Lutathera for pediatric patients 12 years and older with gastroenteropancreatic neuroendocrine tumors. This is the first therapy approved for use in pediatric patients with GEP-NETs. Novartis is a subsidiary of Swiss drug giant Roche.
Benzinga · 1d ago
More
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Webull offers Novartis AG (ADR) stock information, including NYSE: NVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVS stock methods without spending real money on the virtual paper trading platform.